Loading...
•
Jun 30, 2023
Bioxcel Therapeutics Q2 2023 Earnings Report
BioXcel Therapeutics' Q2 2023 performance was marked by a strategic shift towards at-home market opportunities and a reduction in operating expenses.
Key Takeaways
BioXcel Therapeutics reported Q2 2023 financial results, highlighting a strategic reprioritization to focus on high-potential agitation market opportunities and reduce operating expenses. The company is shifting its commercial strategy for IGALMI and reducing its workforce to extend its cash runway through mid-2024.
Strategic reprioritization to focus on high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease.
Commercial reprioritization intended to reduce related expenses by 80% with focus on market access through contracting with large hospital systems (IDNs).
Requested meeting with FDA to discuss TRANQUILITY II, audit plan, and data package to support potential submission of sNDA for BXCL501 in patients with agitation associated with mild to moderate dementia due to probable Alzheimer’s disease.
Cash runway post-strategic reprioritization, expected through mid-2024; discussions underway with existing strategic finance partners.
Forward Guidance
BioXcel Therapeutics is undergoing a strategic reprioritization to focus on at-home market opportunities for BXCL501 and reduce operating expenses. The company expects its current cash and cash equivalents to last through mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...